The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Jun 18, 2012

Keywords

ClinConnect Summary

The Longitudinal CONQUER Study is a clinical trial focused on understanding rare neuroimmunologic disorders, specifically conditions like Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorder (NMOSD), Transverse Myelitis (TM), and Optic Neuritis (ON). The goal of this study is to figure out the biological reasons behind inflammation in these conditions. Researchers want to learn why some patients respond well to treatments while others do not and what happens in the body before a relapse or worsening of symptoms. By collecting data and biological samples from participants, the study aims to identify new ways to diagnose and treat these disorders. The information gathered will be shared with researchers worldwide to improve understanding and treatment options.

To participate in this study, individuals need to be at least 6 years old, and they can be male or female. Participants must have a diagnosis of NMO, NMOSD, TM, or ON and should be able to provide informed consent (or have a parent do so for minors). It’s important to note that participants should be able to attend scheduled visits and cannot have known infections like HIV or hepatitis C. Throughout the study, participants will continue to receive care from their own doctors, while contributing to research that could lead to better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 6 years or greater
• • Male or Female
• • Patient or Parent (in the case of a minor) able to give informed consent
• • For patients 10 to 17, patient able to assent
• • Patient diagnosed with NMO, NMOSD, TM or ON
• Exclusion Criteria:
• • Unable to maintain scheduled visits
• • Patient has known HIV or hepatitis C infection